How many insider trades does FilingIQ track for NMRA?

FilingIQ tracks 123 Form 4 insider transactions for NMRA (Neumora Therapeutics, Inc.), covering filings from Sep 14, 2023 onwards. 4 of those were filed in the last 90 days.

Are NMRA insiders net buyers or net sellers?

Across the full Form 4 history for NMRA, 44 transactions (36%) were open-market purchases and 21 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NMRA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NMRA in?

Neumora Therapeutics, Inc. (NMRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $591.39M.

NMRA insider trading

NasdaqGS Healthcare

Neumora Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

123

Last 90 days

Buys / sells

36% / 17%

Market cap

$591.39M

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Company website: www.neumoratx.com

NMRA insider activity at a glance

FilingIQ has scored 123 insider transactions for NMRA since Sep 14, 2023. The most recent filing in our index is dated Feb 17, 2026.

Across the full history, 44 open-market purchases and 21 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NMRA insider trades is 45.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NMRA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding NMRA

SOFTBANK GROUP CORP.

$75.17M · 0.4% of AUM

Artal Group S.A.

$40.21M · 1.0% of AUM

JOHNSON & JOHNSON (JNJ)

$3.37M · 0.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for NMRA?: FilingIQ tracks 123 Form 4 insider transactions for NMRA (Neumora Therapeutics, Inc.), covering filings from Sep 14, 2023 onwards. 4 of those were filed in the last 90 days.
Are NMRA insiders net buyers or net sellers?: Across the full Form 4 history for NMRA, 44 transactions (36%) were open-market purchases and 21 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NMRA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NMRA in?: Neumora Therapeutics, Inc. (NMRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $591.39M.

Methodology & sources

Every NMRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.